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AIDS:

Implications to Society and
Approaches to Control
By
Robert W. Sidwell
Utah State University
Logan, Utah

Introduction
It is perhaps a measure of today's society that a new disease of potentially
world-wide implication does not gain national or international attention
until a famous person contracts it. This was particularly seen with Acquired
Immunodeficiency Syndrome (AIDS) when it became known that Rock
Hudson of movie and TV acclaim was dying of it. By the time the celebrated
pianist and entertainer Liberacedied of AIDS, the various public health
agencies around the world had begun to focus on the problem, and enormous
sums of money were being committed toward its control. Today, more U.s.
dollars are budgeted for AIDS than are being spent for any other disease,
including cancer (Figure 1).
Figure 1. Federal Funding for AIDS (Combined Public Health Service, Federal Medicaid
Share, Veterans Administration and Department of Defense)
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AIDS has caused major changes in the scientific and social perspectives of
the people of the United States and, perhaps to a lesser degree, to public
1

perspectives throughout the world. This is a deadly disease caused by a new
pathogen of a class which previously has never been conclusively shown to
be a public health problem. We have had to adjust our scientific sights to
focus on this new disease agent-an adjustment which has resulted in
astonishi.ng technological progress in learning of the etiology and means by
which this new disease is spread. Such technological advancements, in
addition to expanding our understanding of this new disease, may
peripherally benefit the public in providing illumination on many other
heretofore little known diseases. Unfortunately, science has thus far fallen
short, however, of finding an acceptable cure for those with AIDS or of
developing a vaccine for those who may be at risk.
The disease is making a major economic impact, both on increasing the
demand for more research dollars and in escalating costs for medical
treatment which has led to significant changes in insurance coverages and
fees. Since a major means of transmission of the AIDS pathogen is through
sexual contact, significant changes in human sexual behavior have been
mandated.
It is the purpose of this lecture to provide a brief overview on AIDS: The
disease, its etiology, some sociological effects and how our government is
responding to the disease. I will end by reviewing some of the research being
done at Utah State University (USU) toward control of this most significant
new medical emergency.

The Disease
The disease of AIDS is not pretty, and people who die due to its effects
usually do not do so quickly. The AIDS virus directly attacks several portions
of the immune system. The primary target cell attacked is the helper T4
lymphocyte, a white blood cell required by the body to initiate the necessary
immune responses to protect the body. The loss of these T4 cells results in a
systematic failure of a large part of the immune system. The virus also
attacks the macrophage, another important white cell which functions in a
variety of ways to provide immunologic protection. The destruction of these
immune mechanisms leaves the body open to attack by what are known as
opportunistic infections, which are caused by viruses, bacteria, fungi, and
protozoa (Table 1) which are of little significance in the healthy individual.
In addition, the patient is highly prone to develop certain cancers; Kaposi' s
sarcoma, a cancer of the skin, and internal organs, is predominant.
The resultant opportunistic diseases are devastating, usually leading to a
slow, and painful death.
The AIDS virus itself can cause clinical manifestations of disease. The
macrophages infected by the virus migrate to many parts of the body and
consequently are instrumental in the spread of the virus to cells of the brain,
central nervous system, and spinal cord. The heart and blood-forming
elements may also be attacked. Individuals infected in this manner often do
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not display either the cancers or infectious diseases usually seen in AIDS
patients. Instead, they exhibit dementia, severe emaciation, and occasional
anemia, and are referred to as having AIDS-related complex (ARC).

Table 1. Opportunistic Infections in AIDS Patients
Common Clinical Manifestations

Organism
Virus
Cytomegalo"
Herpes simplex
Herpes zoster
Epstein-Barr

Retino-choroiditis, colitis, pneumonia
Mucocutaneous (mouth, rectum)
Dermatomal
Hairy leukoplakia, possible neoplasia

Bacteria

Hemophilus influenza
Mycobacterium avium-intracellulare"
Mycobacterium kansasii
Mycobacterium tuberculosis"
Salmonella sp."
Streptococcus pneumoniae
Treponema pallidum

Pediatric upper respiratory, pneumonia, sepsis
Disseminated infection
Disseminated infection
Pneumonia, disseminated infection
Diarrhea, sepsis
Pediatric upper respiratory, pneumonia, sepsis
Neurosyphilis

Fungi

Candida sp.
Coccidiodes immitis"
Cryptococcus neoformans"
Histoplasma capsulatum"

Esophagitis, stomatitis
Disseminated infection
Disseminated infection, meningitis
Disseminated infection

Protozoa

Cryptosporidium
Isospora belli
Pneumocystis carinii"
Toxoplasma"

Enteritis
Enteritis
Pneumonia
Encephalitis, retinochoroiditis

"Considered of major Significance

Epidemiological Impacts

J

Probably the first case of AIDS in the United States involved a 15-year-old
boy who died in 1969. The patient had small purplish lesions which were
identified as Kaposi's sarcoma, and a major onset of chlamydia, a sexually
transmitted viral disease. His immune system was functioning poorly at the
time of his death. Samples of his body fluids and tissues were found 15 years
later to be positive for the AIDS virus. l It is apparent that the virus present in
this youth did not get widely spread, and no further cases of a similar nature
were reported until 1981, when an immunodeficiency disease was seen in
male homosexuals. 2,3 Since that time, the number of cases in this country
has rapidly increased, to a total of 137,385 through June 19904 (Figure 2). By
this latter date, 84,164 deaths have been attributed to the disease in the U.s.
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By 1992, our public health authorities predict over 365,000 cases-at least 1,000
new cases for each day of the year. 5

Figure 2. Increase in Clinical AIDS Cases in the United States, 1981 through 1992 (predicted)
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Some even more sobering statistics also confront us. The numbers just
cited are clinical cases of AIDS. If we also consider those who are seropositive
but do not yet have symptoms, the numbers jump to over one and one-half
million cases in the United States right now. 4 Thus the active cases are
literally only the tip of the iceberg. By redefining of the scope of AIDS to
include seropositive patients with those nearing death from AIDS as having
"HIV disease," our medical authorities have then qualified the clinically
healthy but seropositive patient for insurance benefits. This has subsequently
raised the cost to care for such patients to an enormous extent. 6 Estimates of
the cost for the lifetime care for an AIDS patient have ranged from $61,800 to
$94,000. 6 Such marked increases in healthcare costs will ultimately affect us
all in the pocket book.
None of the above figures reflects the incidence of AIDS outside of the
United States. The disease is considered to be found in essentially all the
nations of the world. In Africa, the World Health Organization has estimated
that at least 400,000 persons have AIDS, and about 3.5 million additional
Africans may be seropositive? Most of these cases have been seen in central
Africa, where literally entire towns have been decimated. We must
recognize, too, that many countries in Africa are reluctant to admit the extent
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of the disease in their area, so there is little doubt the incidence of AIDS is
much higher than now reported.
The AIDS nightmare in Africa and the response of some governmental
officials there to it is illustrated in a recently described situation involving
Tanzania. 8 Researchers at Yale University's international health program
planned to determine the prevalence of HIV disease in pregnant women in
that country. They were to look for antibodies to the AIDS virus in maternal
and infant cord blood. Unfortunately, Tanzanian officials would not allow
the women to be told either why the blood was being taken or what were the
results of the testing. They were concerned that hysteria might develop
among the women because there was no cure for AIDS. In addition,
Tanzania's medical care system was unable to provide adequate supportive
services. Because U.s.-associated trials require "informed consent," the study
had to be abandoned.
The distribution of AIDS cases is interesting. Most of the infected patients
are homosexual or bisexual men, followed by intravenous drug abusers
(Figure 3). Hemophiliacs, transfusion recipients, and adults who participate
in heterosexual activities are the primary other "at risk" groups. Note the
information in the figure are 1986 statistics. Also shown, however, are the
figures predicted for 1992, where it can be seen that a major shift occurs to
sexually active women. We are already seeing this transmission of the AIDS
virus from men to women occurring in much higher frequency.9 Not shown
on the graph is the predicted major increase of AIDS in the perinatal
population. The current U.s. statistics indicate a 38percent increase of the
disease among infants in the past year. 4
The distribution of AIDS cases shifts dramatically in some other
countries. In Africa, for example, women and children are now the hardest
hit. Of the estimated 3.5 million seropositive persons in Africa, children
under five constitute approximately 600,000.7 Infections are almost nonexistent in Africa among homosexuals. Thus, this is a disease which is not
necessarily discriminating and is potentially capable of affecting many
populations. One of the most touching photographs shown by an AIDS
researcher at a recent medical conference was of an African hut with a girl
about 12 years old standing in front of it holding a baby and with a toddler
holding onto her leg. The researcher said that this was quite illustrative of
the situation now occurring in Africa-both the parents had died of AIDS,
and the baby eventually may as well. The entire burden of running the
family had fallen to the 12-year-old.

5

Figure 3. Distribution of AIDS Cases in the United States, 1986 and 1992 (predicted)
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The Virus

The causal agent of AIDS has had several names: lymphadenopathy
virus (LA V), human T lymphotrophic virus III (HTLV-III), AIDS-associated
retrovirus (ARV), and, finally, human immunodeficiency virus (HIV). The
latter name, HIV, is in common use at this time.1 o It now appears that two
types of HIV are responsible for AIDS. Type 1 (HIV-l) is the primary culprit,
but recent evidences point to the emergence of type 2 HIV (HIV-2), which has
similarities to simian immunodeficiency virus, an agent which causes an
AIDS-like disease in nonhuman primates; HIV-2 has now been found in
human populations in certain areas of Africa. II
HIV is a member of the Retroviridae family of viruses, and is thus often
referred to as a retrovirus. Until the onslaught of AIDS, no retrovirus had
been conclusively shown to be a cause of human disease. Retroviruses have
RNA for their genetic material, from which DNA is made which is
incorporated into cells, changing the cells' genetic makeup so that Itew viral
RN A can be synthesized and assembled into new virus particles.
The viral DNA, once incorporated into the cell chromosome, may
undergo a period of latency which can last years. Thus persons infected
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initially with HIV may appear normal for long periods of time before the
AIDS disease eventually develops. Despite the exposure to often very small
amounts of virus through sexual contact, use of contaminated needles by
drug abusers, or transfusions of contaminated blood products, an immune
response to the virus is triggered. Antibodies to HIV subsequently appear in
the blood and are used as ~m indicator of infection. Eventually, the latent
infection is activated, and once this occurs, the virus will grow rapidly, and
spread quickly to other cells throughout the body. The antibodies developed
against the virus do not control the disease, which is in contrast to what
happens in most virus diseases. The virus, in part, is transmitted cell-to-cell
in a manner that it is not accessible to the antibody. Although HIV levels in
the blood often decline with high antibody levels, considerable evidence is
accumulating indicating that the anti-HIV antibodies may actually enhance
the disease severity.1 2 The later destruction of the other immunological
components in the body by the virus then leads to further increases in disease
severity and to the opportunistic infections described earlier.
The AIDS virus is an especially challenging entity. In addition to its
effects on the immune system of the body, the virus also undergoes genetic
variation, often in the same infected individual, during the period of
infection. 12 This mutation of segments of the HIV genome occurs at a much
higher rate than is expected to occur in human genes. Such variations may
pose complications particularly in the development of viral vaccines.
A last point in this most simplified review of a highly complicated
pathogen: HIV is relatively sensitive to destruction by normal conditions
such as heat, light, and drying outside the body. Thus, transmission via
casual contact such as on toilet seats, on lab benches, or breathing potentially
contaminated air is unlikely and as yet has never been demonstrated.
Although mosquitoes have been suspected of HIV transmission, considerable
research has not shown this to occur. If it were not for the various exchanges
of body fluids that occur in the human population, the spread of this virus
would be no problem to us.
The United States Government's Response
The U.S. government's mechanisms for coping with the AIDS problem
were both late in starting and slow to build up to render significant help.
Today, however, as seen in Figure I, the total dollar appropriation into AIDS
research has reached major proportions. An initial review of the figure
might incur the response that too much is being spent on this disease; the
difference between AIDS and diseases such as heart disease, cancer, and
stroke, which now kill many more persons than AIDS, however, is the fact
that the incidence of AIDS is increasing at an extremely rapid rate and
expanding into new populations, whereas the other diseases, while at a high
rate, are not increasing in such a dramatic fashion.

7

The federal approach has been multipronged, involving a major Public
Health Service task force including the Centers for Disease Control, the
National Institute of Allergy and Infectious Diseases (NIAID), the National
Cancer Institute, the National Institute of Mental Health, the National
Institute of Drug Addiction, the Food and Drug Administra tion, the
Department of Defence, the Veteran Administration, and the Health
Resources Services Administration.
Within the NIAID, a new division has been formed, appropriately named
the Division of AIDS. This Division has an Epidemiology Branch, a
Biostatistics Research Branch, a Treatment Research Program, and a Basic
Research and Development Program. These programs encourage and
coordinate research involving much collaboration between medical workers
and research scientists from the NIH itself, universities, nonprofit research
institutes, pharmaceutical companies, and the rapidly multiplying
biotechnology companies. With the innovative new Nationai Cooperative
Drug Discovery Programs, it is not unusual for one grant application to have
many subapplications, each from a different institution.
A significant response by our government to the AIDS problem has been
the literal "new age" of drug testing which aims to provide promising drugs
to as many AIDS patients as possible. The drug testing concept, which has
developed in part due to recommendations of AIDS activists, involves people
with AIDS in the trial design, puts more emphasis on drugs for opportunistic
infections, uses more flexible testing protocols and broader entry
requirements, avoids the use of placebos, and involves the use of more
sensitive disease parameters instead of death of the patient)3 In addition,
considerable flexibility is being displayed by the U.s. Food and Drug
Administration to get more new drugs into clinical trials faster. Such
monumental changes in drug testing may go beyond the treatment of AIDS to
apply to testing of drugs against other life-threatening diseases. 13
The AIDS research effort has begun to mature, and without question, no
other virus has had so much learned about it so quickly .. More is known
about HIV than is known about any other virus. Unfortunately, as has been
reviewed, the virus is so complex, and the disease manifestations so
extensive and challenging, that much more needs to be learned before the
disease can be controlled or adequately treated.
Treatment Difficulties
Treatment of AIDS patients is being approached from several directions.
Before reviewing the approaches to AIDS treatment, which is the thrust of
our USU research, we should first consider the challenges involved in
attempting such treatments.
Since the AIDS virus becomes a part of the infected cell, often in a latent
state for long time periods, the virus potentially may never be removed from
the body by therapy, and treatments may need to be continued throughout the
8

lifetime of the infected individual. The occasional infection of brain tissues is
a particular challenge to drugs, for they must cross the blood-brain barrier,
which is high in lipid content and consequently almost impervious to any
drugs not soluble in lipids. In addition, such therapies involving the brain
should avoid having neurological effects, a complication difficult to avoid
when drugs are found which can penetrate nervous tissue.
Since the host's immune response has been compromised or perhaps
essentially destroyed by the HIV infection, the body cannot assist the antiviral
therapy, which often acts by inhibiting the viral growth but by itself does not
eliminate the virus; the sagging immune response may need bolstering by an
immune modulating drug which may thus be required to be used in
combination with more standard antiviral therapies.
The opportunistic infections which are usually the cause of death in the
AIDS patient consist of a spectrum of disease agents, each requiring a different
specific type of treatment. For some opportunistic pathogens, no therapies are
yet known. Ideally, treatment may consist of therapy to stop the HIV
combined with a drug or drugs to combat the opportunistic infection. Finally,
the specter of drug-resistant viruses needs to be confronted. This is already
beginning to be a problem. 14
Treatment Concepts

Considering the above difficulties, treatment of AIDS can theoretically be
approached by:
1. Anti-HIV therapy using a substance designed to attack the virus or to
inhibit its growth (Table 2).

2. Anti-HIV therapy using cytokines, which are biological response
modifiers produced by cells and which are becoming available in sufficient
quantities to be of potential clinical use (Table 3).

Table 2. Substances Now in Use or in Clinical Evaluatioll as Specific Anti-HIV Therapies 15
2',3' -Dideoxyadenosine (DDA)
2',3'-Dideoxycytidine (DDC)
2' ,3' -Dideoxyinosine (DDI)
Acyclovir
AL-721
Amphotericin B
Ansamycin
Avarol
AZidothymidine (AZT)
Carrisyn·
Cyanothymidine (CNT)

D-Penicillamine
Dextran sulfa te
Foscarnet
Fusidic acid
GLQ223 (Compound Q)
Glycyrrhizin sulfate
HOE/BAY 946
Hypericin
Lentinan
Peptide T
Ribavirin

• Also has immunomodulatory properties
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Table 3. Cytokine Anti-HIV Therapies U"der Cli"ical Investigation 15
Anti-HIV antibodies
Colony-stimulating factor
Gamma globulin
Interferon a, b, g
Interleukin-I, 2, 3, 4

Leukotoxin
Thymosin-a 1
Transfer factor
Tumor necrosis factor

3. Anti-HIV therapy using materials that block viral entry into cells.
These include peptide T, which is part of the envelope glycoprotein of HIV;
CD4, the protein receptor on certain cells to which HIV binds; and the
polysaccharide, polymannoacetate.
4. Stimulation of certain segments of the immune response using
immunomodulators as a means of strengthening the system or to provide
backup to any of the above HIV therapies (Table 4).

Table 4. Immune Stimulators Under Clinical Investigation as Anti-AIDS Therapies 15
Imuthiol
Isoprinosine
LF1695
Methionine-enkephaline (MET-ENK)
M uramyl tripeptide
Naltrexone
Thymopentin

Ampligen
AS-1OI
Azimexon
Carrisyn
CL246,738
Cyclosporin
Imreg-I

5. Specific treatment of the opportunistic infection(s) occurring in the
AIDS patient, including anticancer therapy for Kaposi's sarcoma. These are
too extensive to discuss in this overview.
6. Use of vitamins and appropriate diet to build up the patient.
7. Selective destruction of HIV-infected cells resulting also in the
elimination of the virus. This approach to date involves the use of
immunotoxins, which are combinations of antibody against the cell to be
killed conjugated with a toxic substance. The toxic substance is harmless
unless it can be taken-into the cell-an event requiring the antibody to which
it is attached.
8. Perfusion of the AIDS patients' plasma through a prosorba column
which removes circulating immune complexes which are involved in AIDS
pathogenesis, blocking normal immune responses.
9. Use of vaccines against all or part of the HIV genome. While not a
treatment, it may be appropriate to include as the last approach in this review,
although work with vaccines is literally the topic of a complete review in
10

itself. While early results with vaccines show some promise, much research
remains to be done.
Utah State University Studies
The above review of the means to treat AIDS appropriately leads to a brief
description of the AIDS research underway at USU. Our AIDS Research
Group presently has two contracts with the National Institutes of Health; one
is oriented toward developing therapies for a viral opportunistic infection
associated with AIDS; in the other, research is being done into developing
therapies for AIDS.

Therapy for opportunistic infections: The project to develop an agent for
treatment of opportunistic infections is a collaborative study with chemists at
SRI International (Menlo Park, California). Potential new drugs synthesized
at SRI are evaluated against experimentally induced cytomegalovirus
infections and for potential toxicologic effects in our laboratories. Two
potential new drugs which are chemically related to ganciclovir, the only
clinically approved drug for treating human cytomegalovirus infections,
have been developed through this joint research effort. These substances are
the phosphonate monoethyl ester of ganciclovir and the phosphonate diacid
of ganciclovir.1 6 Both new substances appear to be less toxic than ganciclovir,
yet retain a strong antiviral potency (Table 5). Much is yet to be done in the
development of these materials as drugs.
Table 5. Treatment for Opportunistic Infections: Human Cytomegalovirus Inhibition of
Phosphonate Analogs of Ganciclovir

Compound

Ganciclovir
Phosphonate diacid
of ganciclovir
Phosphonate monoethylester of
ganciclovir
"Cytotoxic dose

+

50% Cytotoxic
Dose (Jlg/ml)

50% CytomegalovirusInhibitory Dose (Jlg/ml)

Therapeutic
Index"

1000

2

500

-2000

2

1000

-2000

4

500

virus-inhibitory dose.

Studies with unique AIDS animal model: The research work to develop
new therapies for AIDS underway at this university is involved particularly
in the study of immunomodulators for the potential therapy of AIDS. Such
research is challenging because we must use a small animal model which
mimics, as much as possible, the AIDS disease in humans. The AIDS virus
will not produce a disease in animals other than primates. A retrovirus of
mice is thus employed, this being the Friend virus complex, which receives
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its name from the scientist, Dr. Charlotte Friend, who originally discovered it.
The Friend virus induces in mice a leukemia-like disease which will vary
according to the genetic makeup of the animal. When special hybrid mice
with the Rfv-3r / s, H-2 a / a and FV-3 r / s genotype are infected, the resultant
disease has many analogies to AIDS: in both infections, immunosuppression
of the host occurs. Antibodies specific to the retrovirus occur in both the
hybrid mouse and in man, yet both hosts are immunologically compromised
if challenged by other disease agents. With the development of the antibody,
only low levels of infectious virus can be found, yet the disease continues to
progress.
Our laboratory is unique in using this special mouse with defined genetic
characteristics for use as an AIDS animal modeP7 We have found the
clinically useful HIV-inhibiting drug zidovudine (AZT), to markedly inhibit
the AIDS-like disease in this mouse model. Of considerable significance,
however, is our recent finding 18 that infected animals treated with AZT may
appear to be "cured," i.e., free of all signs of the disease, including virus as
sought by standard means. An apparently latent virus can still be seen,
however, when extraordinary means are used for virus detection involving
multiple co-cultivations of tissues from the animal with cultured cells of
normal mice (Table 6).

Table 6. Detection

of Persisting Retrovirus in AZT-Treated Mice
Total Virus-positive
Spleens Detected" by
Standard Methodology

Total Virus-positive
Spleens Detected" After
Viral Amplification ....

AZT, 80 mg/kg tid x 20

0/31

14/31

Saline tid x 20

6/10

10/10

Treatment

"35 weeks after virus inoculation .
....Multiple co-cultivation with cultured indicator cells.

Such results lend credence to the cry for new, better drugs for treatment of
AIDS. As mentioned earlier, a possible approach for improving the efficacy of
an antiviral drug such as AZT is to use a second drug in combination with
the original antiviral drug. Ideally, the second drug should have a
mechanism of action quite different from the initial drug. This is where the
immunomodulators enter the scene, for the mechanisms by which these
materials act are to enhance or modify the host immune system. Thus, a
drug like AZT may specifically inhibit the replication of the virus in the cell,
while the immunomodulating drug acts to bolster the fading immunity
which results from the HIV infection. Such combinations are beginning to be
studied in the clinic; it is one goal of the USU AIDS Research Program to help
identify which combinations may be best for use in those clinical situations.
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Our studies to date indicate 3 immunomodulators have potential for use in
drug combinations. These materials are recombinant human interferon a,
pyran copolymer (also known as MVE-2), and imexon, which has the
chemical name 4-imino-1,3-diazobicyclo-(3.1.0)-hexan-2-one. 19

Use of genetically immunodeficient mice: A problem often encountered
with potential irnrnunomodulating drugs is their failure to achieve in
humans the significant immune modulation seen in lower animals such as
mice. An approach being taken at USU is again to use a unique mouse
model, in this case the Severe Combined Immunodeficient animal, usually
referred to as the SCID mouse. These mice lack functional T or B cells, are
hypogamma-globulinaemic, poor mitogen responders, and fail to reject
allogenic skin grafts. 20 In short, the animals are so lacking in a functional
immune system that they are unable to reject foreign tissues introduced into
their bodies. Thus, portions of a human immune system, such as found in
human lymphocytes, can be injected into the SCID mouse, and, rather than
being quickly eliminated by the animal, grow in the animal, literally
reconstituting the mouse with the human immunity.21,22 We are using
these human immunity-reconstituted SCID mice as a "next step" in the
process of evaluating Biological Response Modifiers (BRM). It is most
encouraging when a BRM will stimulate segments of the reconstituted
human immune system in the SCID mouse in a similar manner to what is
seen in regular mice.
The immunological deficiencies of the SCID mouse have been shown by
our group23 to allow the animals to become infected by Cryptosporidium, a
serious parasitic infection afflicting AIDS patients. Until this infection was
demonstrated in the SCID mouse, researchers have had difficulty finding an
acceptable model which could be used to study this disease and the effects of
possible therapies upon it.

Transgenic animal research: A last challenge being targeted by our
research program is how to deal with the latent virus or portion of the HIV
genome which is being continually passed from one cell to its offspring.
Again, a model is needed. In this case, we are collaborating with researchers
at the Roche Institute of Molecular Biology (Nutley, New Jersey), and at the
National Institutes of Health (Bethesda, Maryland) in the development of
transgenic mice. 24 Noninfectious segments of the HIV gene are inserted
directly by micromanipulation into the fertilized mouse embryo, which in
turn is transplanted into a healthy female mouse. The subsequent offspring
are born with the HIV gene segment being expressed in certain of its tissues
and are referred to as transgenic animals. The HIV gene segment is expressed
in immune cells of the skin and can be activated to be expressed in
lymphocytes and macrophages by factors known to activate the virus in HIVinfected people. The offspring born later to these HIV gene-expressing mice
similarly express the same gene, somewhat analogous to what occurs in man.
We now have small colonies of these transgenic animals which are being
used for the study of potential anti-AIDS drugs and BRMs.
13

Conclusions
This brief overview has hopefully shown that AIDS is a most serious
affliction which is spreading rapidly, and, as yet, is not readily controlled. The
government's massive basic and clinical research response to this disease has
yielded dramatic advances and will benefit us in control of other illnesses.
Many approaches are being taken to the treatment of AIDS, and numerous
therapies are under evaluation. The much sought-after cure of this deadly
disease is probably still much into the future, however.
The USU research programs I have described are a result of a truly
collaborative effort involving scientists of many disciplines both from within
the university as well as from highly regarded outside institutions (Table 7).
Indeed, collaboration in research is the key for success in the battle against a
most formidable and serious new plague, the disease of AIDS.
Table 7. Senior Researchers Involved With the Utah State University AIDS Research
Program
USU Researchers
Robert W. Sidwell
John D. Morrey
Reed P. Warren
John H. Huffman
Donald F. Smee
Dale L. Barnard

Thomas Bunch
Mark C. Healey
Kevin Jackson
Michael Arrowood
Jan Mead
Kathleen Rasmussen
Outside Collaborators

Michael Hogan, Baylor College of Medicine
Malcolm Martin, National Institutes of Health
Elmer Reist, SRI International
Craig Rosen, Roche Institute for Molecular Biology
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